MAPS technology may generate vaccines conferring strong immunity at reduced cost and risk
A new method of vaccine design, called the Multiple Antigen Presentation System (MAPS), may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination. The method, pioneered by researchers at Boston Children’s Hospital, permits rapid construction of new vaccines that activate mulitple arms of the immune system simultaneously against one or more pathogens, generating robust immune protection with a lower risk of adverse effects.
As reported by Fan Zhang, PhD, Ying-Jie Lu, PhD, and Richard Malley, MD, from Boston Children’s Division of Infectious Disease, in the Proceedings of the National Academy of Sciences on July 29, the method could speed development of new vaccines for a range of globally serious pathogens, or infectious agents.
Broadly speaking, the vaccines available today fall into two categories: whole-cell vaccines, which rely on weakened or killed bacteria or viruses; and acellular or subunit vaccines, which include a limited number of antigens—portions of a pathogen that trigger an immune response. Both approaches have advantages and disadvantages.
“Whole-cell vaccines elicit a broad range of immune responses, often just as an infection would, but can cause side effects and are hard to standardize,” said Malley. “Acellular vaccines can provide good early immunity with less risk of side effects, but the immune responses they induce wane with time.”
The MAPS method may allow vaccine developers to take a middle ground, where they can link multiple protein and polysaccharide (sugar) antigens from one or more pathogens together in a modular fashion, much as one would connect Lego blocks.
The resulting complex—which resembles a scaffold of polysaccharides studded with proteins—can stimulate both antibody and T-cell responses simultaneously much like whole-cell vaccines, resulting in stronger immunity to the source pathogen(s). However, because the composition of a MAPS vaccine is well defined and based on the use of isolated antigens (as one would find with an acellular vaccine) the risk of side effects should be greatly reduced.
For instance, mice injected with a MAPS vaccine combining proteins from tuberculosis (TB) and polysaccharides from Streptococcus pneumoniae (pneumococcus) mounted vigorous antibody and T-cell responses against TB, whereas those vaccinated with TB protein antigens alone mounted only an antibody response.
Similarly, 90 percent of mice given a MAPS-based vaccine containing multiple pneumococcal polysaccharide and protein antigens were protected from a lethal pneumococcus infection, mounting strong antibody and T-cell responses against the bacteria. By contrast, 30 percent of mice vaccinated with the same antigens in an unbound state survived the same challenge.
“The MAPS technology gives you the advantages of: whole-cell vaccines while being much more deliberate about which antigens you include; doing it in a quantitative and precise way; and including a number of antigens so as to try to replicate the effectiveness of whole-cell vaccination,” Malley explained. “The immunogenicity of these constructs is greater than the sum of their parts, somewhat because they are presented to the host as particles.”
The system relies on the interactions of two compounds, biotin and rhizavidin, rather than covalent binding as is used in most of the current conjugate vaccines. To build a MAPS vaccine, biotin is bound to the polysaccharide(s) of choice and rhizavidin to the protein(s). The biotin and rhizavidin then bind together through an affinity interaction analogous to Velcro. The construction process is highly efficient, significantly reducing the time and cost of vaccine development and production.
The Latest on: Vaccine design
- Protein design named an Audacious project on April 17, 2019 at 12:15 pm
"We believe that protein-based technologies will play an increasingly transformative role in this space," said Neil King, an assistant professor of biochemistry at the UW School of Medicine, who leads ... […]
- Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk on April 17, 2019 at 2:22 am
Here we report two crystal structures of the antibody BDBV223, alone and complexed with its GP2 stalk epitope, an interesting site for therapeutic/vaccine design due to its high sequence conservation ... […]
- Institute for Protein Design wins $45M in funding from TED’s Audacious Project on April 17, 2019 at 1:00 am
“They are things that we’ve been thinking about for a while, and are starting to work toward,” said Neil King, who leads the institute’s vaccine design efforts. “We’re really excited by the ... […]
- Workshop on chemistry of vaccine, immunology on April 16, 2019 at 6:51 pm
Also, as a part of SPARC (Scheme for Promotion of Academic and Research Collaboration) visit at PU, Prof Nikolai Petrovsky delivered a talk entitled ‘Intelligent Vaccine Design’ at the IIT-Ropar and ... […]
- UW institute developing lifetime flu vaccine gets $45 million award on April 16, 2019 at 5:13 pm
Protein design used to be done by tweaking existing proteins or searching for new kinds of naturally occurring proteins. The ability to create new proteins opens the door to projects like a vaccine ... […]
- UW's Institute of Protein Design receives $45M from the Audacious Project on April 16, 2019 at 4:05 pm
... Protein Design at the University of Washington School of Medicine will receive $45 million to add staff to help design a flu vaccine to last a lifetime and other innovative projects. “It comes at ... […]
- Doe v. Merck: Vaccine Autism Lawsuit Dismissed as Baseless on April 16, 2019 at 3:43 pm
The High Court held in a split decision that the Act preempts design defect claims against vaccine manufacturers. Unlike in tort suits, claimants under the Act are not required to show that the ... […]
- Workshop on chemistry of vaccine and immunology on April 16, 2019 at 9:15 am
And on Tuesday, as a part of SPARC visit at PU, Dr Nikolai Petrovsky delivered a talk entitled ‘Intelligent Vaccine Design’ at IIT Ropar and CSIR IMTECH. Also, an international workshop was ... […]
- Ebola survivors' immune responses offer clues for vaccine development on April 11, 2019 at 3:00 pm
But the immune response to the virus is still not fully understood, which makes improving vaccine design a challenge. Now, scientists in France have found some clues to improving the vaccines by ... […]
- Vaccine halts the spread of metastatic cancer in patients on April 11, 2019 at 7:59 am
The vaccine is specifically created according to a patient’s ... “If we were going to think about curing patients with metastatic disease, with advanced cancer, then we had to design therapies that ... […]
via Google News and Bing News